l carnitine myopathy Role of in disease | Nutrition & Metabolism Schematic representation of L-carnitine transport
Description
Skvarc DR, Dean OM, Byrne LK, Gray L, Lane S, Lewis M, et al
= from 0.026 to 0.028 for each CFS subgroup)
Leucine 2.7g
Patients with severe kidney disease or end-stage renal disease may not be appropriate candidates for this therapy, particularly if they have significant fluid retention or are prone to dehydration
